State Street Corp Werewolf Therapeutics, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 476,439 shares of HOWL stock, worth $781,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares

476,439

Previous 423,911 12.39%

Holding current value

$781,359

Previous $1.03 Million 2.32%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.71 - $2.95 $89,822 - $154,957	52,528 Added 12.39%	476,439 $1.01 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $6.75 $825,418 - $2.38 Million	352,743 Added 495.65%	423,911 $1.03 Million
Q1 2024 May 15, 2024	SELL	$3.92 - $7.91 $48,216 - $97,293	-12,300 Reduced 14.74%	71,168 $461,000
Q4 2023 Feb 14, 2024	BUY	$1.78 - $4.15 $58,206 - $135,705	32,700 Added 64.41%	83,468 $322,000
Q1 2023 May 15, 2023	BUY	$1.98 - $4.3 $35,244 - $76,540	17,800 Added 53.99%	50,768 $131,000
Q4 2022 Feb 14, 2023	BUY	$1.53 - $4.73 $12,852 - $39,732	8,400 Added 34.19%	32,968 $67,000
Q2 2022 Aug 15, 2022	SELL	$3.43 - $5.98 $1.07 Million - $1.86 Million	-310,519 Reduced 92.67%	24,568 $100,000
Q1 2022 May 16, 2022	BUY	$3.71 - $12.22 $279,960 - $922,133	75,461 Added 29.07%	335,087 $1.47 Million
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.65 $1.65 Million - $2.53 Million	143,562 Added 123.69%	259,626 $3.09 Million
Q3 2021 Nov 15, 2021	BUY	$13.89 - $20.31 $525,417 - $768,266	37,827 Added 48.35%	116,064 $1.99 Million
Q2 2021 Aug 16, 2021	BUY	$11.6 - $17.44 $907,549 - $1.36 Million	78,237 New	78,237 $1.36 Million

Others Institutions Holding HOWL

# of Institutions

Shares Held

31.8M

Call Options Held

700

Put Options Held

500

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $48.4M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Werewolf Therapeutics, Inc. Transaction History